Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

@article{Kishi2013EfficacyAT,
  title={Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  author={T. Kishi and N. Iwata},
  journal={CNS Drugs},
  year={2013},
  volume={27},
  pages={731-741}
}
  • T. Kishi, N. Iwata
  • Published 2013
  • Medicine
  • CNS Drugs
  • BackgroundPerospirone is a second-generation antipsychotic (SGA) used only in Japan, and acts as a serotonin (5-HT)1A receptor partial agonist, 5-HT2A receptor inverse agonist, and dopamine (D)2, D4, and α1-adrenergic receptor antagonist. To our knowledge, no meta-analysis addressing the efficacy and effectiveness of perospirone in schizophrenia has been published to date.ObjectiveThe aim of the study was to identify the characteristics of perospirone by assessing the efficacy, discontinuation… CONTINUE READING
    Antipsychotics and the Dopamine-Serotonin Connection
    • 11

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 21 REFERENCES
    Measuring inconsistency in meta-analyses
    • 31,342
    • Open Access
    Meta-analysis in clinical trials.
    • 27,218
    • Open Access
    The positive and negative syndrome scale (PANSS) for schizophrenia.
    • 15,116
    • Open Access
    Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    • 1,490
    • Open Access
    Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
    • 795
    • Open Access